We’re launching Lyria 3.5 in Google Flow Music, with advances across musicality, lyrics, vocals, and creative control
deepmind.google·6d ago
AI Engineering
Hacker News·Jun 21·5 min read
FDA advisors unanimously vote to approve Moderna's mRNA after agency drama
TL;DR
There was initial resistance to reviewing Moderna's mRNA flu vaccine due to political interference. The vaccine, named mRNA-1010 and branded as mFlusiva, was evaluated by FDA advisors who found it 27% more effective than standard flu shots.
✦ Why It Matters
Engineers and researchers can leverage insights from mRNA technology to enhance vaccine development and efficacy assessments.
Key Takeaways
- Understand the impact of political factors on vaccine approval processes.
- Explore mRNA technology applications in other vaccine developments.
- Analyze efficacy metrics from clinical trials for better vaccine design.
- Consider safety profiles as critical components in vaccine evaluation.
Full Summary
Political interference previously delayed the review of Moderna's mRNA flu vaccine, mRNA-1010, which is branded as mFlusiva. In a recent meeting, the FDA's advisory committee, known as VRBPAC (Vaccines and Related Biological Products Advisory Committee), reviewed extensive data from Phase 3 trials.
One trial involved over 40,000 adults aged 50 and older, showing that mRNA-1010 was approximately 27% more effective against seasonal flu compared to standard flu vaccines. Another trial with nearly 3,000 participants aged 65 and older indicated that this vaccine elicited stronger immune responses than the recommended high-dose flu vaccine for that age group.
The safety profile was also deemed generally good. Experts praised the robustness of the studies, highlighting the clear and significant efficacy results.